A two-illness model of bipolar disorder 1

Bipolar Disorders

Volumn 1, Issue 1, 1999, Pages 25-30

  Joffe, Russell T ^a   Young, L Trevor ^a   MacQueen, Glenda M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bipolar disorder; Depression; Mania

Indexed keywords

ANTIDEPRESSANT AGENT; TRANQUILIZER;

ARTICLE; BIPOLAR DISORDER; DIFFERENTIAL DIAGNOSIS; HOSPITALIZATION; HUMAN; PSYCHOLOGICAL ASPECT;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DIAGNOSIS, DIFFERENTIAL; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 0033188535     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.1999.10107.x     Document Type: Article

References (41)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press, 1994.
2. Leonhard K. Aufpluing Der Endogner Psychosen. Berlin: Academie Verlag, 1957.
3. Angst J, Perris C. Zur Nosologie Endogner Depressionen. Archives Fur Psychiatrishe Zeitschrift Ges Neurologie 1978; 210: 373-386.
4. Swann AC. Is bipolar depression a specific biological entity? In: Young LT, Joffe RT, eds. Bipolar Disorder: Biological Models and Their Clinical Application. New York: Dekker, 1994; 255-286.
5. Katz MM, Robbins E, Croughan J, Secunda S, Swann AC. Behavioral measurement and drug response characteristics of unipolar and bipolar depression. Psychol Med 1982; 12: 25-36.
6. Leibenluft E, Clark CH, Myers FS. The reproducibility of depressive and hypomanic symptoms across repeated episodes in patients with rapid-cycling bipolar disorder. J Affect Disord 1995; 33: 83-88.
7. Mitchell P, Parker G, Jamieson K, Wilhem K, Hickey I, Brodaty H, Boyce P, Hadzi-Pavlovic D, Roy K. Are there are differences between bipolar and unipolar melancholia? J Affect Disord 1992; 25: 97-105.
8. Thase ME, Mallinger AG, McKnight D, Himmeloch JM. Treatment of imipramine resistant recurrent depression. IV. A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195-198.
9. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psycliopharmacol 1996; 16: 45-145.
10. Wehr TA, Goodwin FK. Can antidepressants cause mania or worsen the course of affective illness? Am J Psychiatry 1987; 144 :403-411.
11. Zornberg GL, Pope HG. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993; 13: 397-408.
12. Robins E, Guze S. The establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry 1970; 126: 983-987.
13. Thase ME, Himmelhoch JM, Mallinger AG, Jarrett DB, Kupfer DJ. Sleep EEG and BST findings in anergic bipolar depression. Am J Psychiatry 1989; 146: 329-333.
14. Leibenluft E, Clark CH, Myers FS. The reproducability of depressive and hypomanic symptoms across repeated episodes in patients with rapid cycling bipolar disorder. J Affect Disord 1995; 33: 83-88.
15. Mitcliell P, Parker G, Jamison K, Wilhelm K, Hickey I, Brodaty H, Boyce P, Hadzi-Pavlovic D, Roy K. Are there any differences between bipolar and unipolar melancholia? J Affect Disord 1992; 25: 97-105.
16. Cassano GB, Akiskal HS, Musetti L, Purugi G, Soriani A, Mignani V. Psychopathology, temperament and past course in primary major depression. II. Toward a redefinition of bipolarity with a new semi-structured interview for depression. Psychopathology 1989; 22: 278-288.
17. Coryell W, Dicott J, Macer JD, Mueller T, Lavori P, Keller N. The likelihood of recurrence and bipolar affective disorder: the importance of episode recency. J Affect Disord 1995; 33: 201-206.
18. Post RM, Weiss SRB. Endogeneous biochemical abnormalities in affective illness: therapeutic vs. pathogenic. Biol Psychiatry 1992; 32: 469-484.
19. Swann AC, Koslow SH, Katz MN, Maas JW, Gervaid J, Secunda SK, Robins E. Lithium carbonate treatment of mania: cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. Arch Gen Psychiatry 1987; 44: 345-354.
20. Post RM, Weiss SRB. Kindling and stress sensitization. In: Young LT, Joffe RT, eds. Bipolar Disorder: Biological Models in a Clinical Application. New York: Dekker, 1994; 93-126.
21. Brown RA, Monti PM, Myers MG, Martin RA, Rivinus T, Dubreuil ME, Robsenow DJ. Depression among cocaine abusers in treatment: relationship to cocaine and alcohol use and treatment outcome. Am J Psychiatry 1994; 155: 220-226.
22. Koob GB, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988; 242: 715-723.
23. Abrams R, Hayman MA, Krisha NR. Unipolar mania revisited. J Affect Disord 1979; 1: 59-68.
24. Coryell W. Bipolar II disorder: the importance of hypomania. In: Goldberg JEF, Harrow M, eds. Bipolar Disorders: Clinical Course and Outcome. Washington, London, England: American Psychiatric Press, 1999; 219-237.
25. Goodwin FK, Jamison KR. Manic Depressive Illness. London: Oxford University Press, 1990.
26. Berrettini WH. Linkage studies of bipolar syndromes. In: Young LT, Joffe RT, eds. Bipolar Disorder, Biological Models and Their Clinical Application. New York: Dekker, 1994; 219-234.
27. Mass JW, Coslow SH, Davis JM, Katz MM, Frazer A, Bowden CL, Berman N, Gibbons R, Stokes PE, Landis DH. Catecholamine metabolism and disposition in healthy and depressed subjects. Arch Gen Psychiatry 1987; 44: 337-344.
28. Wang JF, Li PP, Warsh JJ, Young LT. Signal transduction abnormalities in bipolar disorder. In: Young LT, Joffe RT, eds. Bipolar Disorder: Biological Models in a Clinical Application. New York: Dekker, 1994; 41-80.
29. Schou M. Lithium Treatment of Manic-Depressive Illness: A Practical Guide, 5th edn. New York: S Karger, 1993.
30. Ballenger JP, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 7: 782-790.
31. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PT, Petty S, Disalver SC, Davis JM, Rush AJ, Small JT, Garza-Trevino ES, Risch SC, Goodnick TJ, Morris BD. Eficacy of divalproex vs. lithium and placebo in the treatment of mania. JAMA 1994; 271: 918-924.
32. Katz MN, Koslow SH, Maas JW, Frazer A, Bowden CL, Casper J, Croughan J, Kocsis J, Redmond E, Jr. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med 1987; 70: 297-309.
33. Swann AC, Koslow SH, Katz MM, Maas JW, Jevaid J, Secunda SK, Robbins E. Lithium carbonate treatment of mania: cerebrospinal fluid and urinary monoamine metabolites and treatment outcome. Arch Gen Psychiatry 1987; 44: 345-354.
34. Koslow SH, Maas JW, Bowden C, Davis JM, Hannin I, Jevaid J. Cerebrospinal fluid and urinary biogenic amines and metabolites in depression, mania and healthy controls. Arch Gen Psychiatry 1983; 40: 999-1010.
35. Baldassano CF, Sachs GS, Stole AL. Peroxetine for bipolar depression: outcome in patients failing prior antidepressant trials. Depression 1995; 3: 182-186.
36. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacies in depressive illness. Drugs 1986; 32: 481-508.
37. Himmeloch JM, Thase ME, Mallinger AG. Tranylcypromine vs. Imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916.
38. Post RM, Uhde TW, Roy-Byrne P, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29-34.
39. McElroy SL, Keck PE, Pope HG, Jr, Hudson JI, Jr. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 1992; 12 (Suppl): 42S-52S.
40. Bunney WE, Jr, Murphy DL, Goodwin SK, Borgef F. 'Switch process' in manic-depressive illness. Arch Gen Psychiatry 1972; 27: 295-302.
41. Lewis JL, Winokur G. The induction of mania: a natural history study with controls. Arch Gen Psychiatry 1982; 39: 303-306.